Megace

Megestrol acetate, the active ingredient in Megace, is a progestin presented as an oral tablet for oral use. It is employed to stimulate appetite and to provide antineoplastic hormone therapy in patients with AIDS‑related cachexia, cancer‑related anorexia, advanced breast cancer, and endometrial carcinoma.

GNH USA supplies Megace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product documentation for global distribution.

Megace is used in several clinical situations that involve severe weight loss or hormone‑responsive cancers.

Cachexia associated with AIDS: improves appetite and promotes weight gain in patients with HIV‑related wasting. Cancer‑related anorexia: increases caloric intake and helps stabilize body mass in oncology patients. Advanced breast cancer: provides antineoplastic hormone therapy to slow disease progression. Endometrial carcinoma: acts as a hormonal treatment for certain stages of endometrial cancer.

Megace may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Edema - Fatigue

Serious or Rare Side Effects: - Thromboembolic events (deep‑vein thrombosis, pulmonary embolism) - Adrenal insufficiency - Severe hyperglycemia or Cushingoid syndrome

Before initiating Megace, clinicians should consider several safety measures.

Monitor blood glucose: check fasting glucose regularly as hyperglycemia may develop. Observe blood pressure: hypertension can occur, especially in high‑risk patients. Assess thromboembolic risk: evaluate history of clotting disorders before initiating therapy. Review hepatic function: liver enzymes may rise; monitor liver tests periodically. Avoid use in known hypersensitivity: discontinue if allergic reaction occurs. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Megace can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - CYP3A4 inducers (rifampin, phenytoin, carbamazepine): may reduce Megace plasma levels. - Anticoagulants (warfarin): increased risk of clotting may be potentiated. - Glucocorticoids: additive effects on glucose and fluid retention.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: may require dose adjustment due to altered glucose control. - Antihypertensive drugs: blood pressure may rise, necessitating monitoring. - NSAIDs: combined use can increase gastrointestinal irritation. - Hormonal contraceptives: efficacy may be reduced, consider alternative contraception. - Digoxin: possible increase in serum concentration, monitor levels.